Matthew J. DamasiewiczDepartment of Nephrology, Monash Health, Clayton, Victoria, Australia and Department of Medicine, Monash University, Clayton, Victoria, Australia
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. 285: 785–795, 2001
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. 285: 785–795, 2001)| false
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, et al.: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). 69: 1945–1953, 2006
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, et al.: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). 69: 1945–1953, 2006)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL, et al.: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int92: 26–36, 2017PubMed
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL, et al.: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int 92: 26–36, 2017PubMed)| false
KanisJA, JohnellO, OdenA, JohanssonH, McCloskeyE: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int19: 385–397, 2008PubMed
KanisJA, JohnellO, OdenA, JohanssonH, McCloskeyE: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385–397, 2008PubMed)| false
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl76: 1–130, 2009
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 76: 1–130, 2009)| false
JadoulM, AlbertJM, AkibaT, AkizawaT, ArabL, Bragg-GreshamJL, et al.: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int70: 1358–1366, 2006PubMed
JadoulM, AlbertJM, AkibaT, AkizawaT, ArabL, Bragg-GreshamJL, et al.: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358–1366, 2006PubMed)| false
WestSL, JamalSA, LokCE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant27: 2384–2388, 2012PubMed
WestSL, JamalSA, LokCE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant 27: 2384–2388, 2012PubMed)| false
WagnerJ, JhaveriKD, RosenL, SundayS, MathewAT, FishbaneS: Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant29: 146–151, 2014PubMed
WagnerJ, JhaveriKD, RosenL, SundayS, MathewAT, FishbaneS: Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 29: 146–151, 2014PubMed)| false
KlawanskyS, KomaroffE, CavanaughPFJr, MitchellDY, GordonMJ, ConnellyJE, et al.: Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int14: 570–576, 2003PubMed
KlawanskyS, KomaroffE, CavanaughPFJr, MitchellDY, GordonMJ, ConnellyJE, et al.: Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14: 570–576, 2003PubMed)| false
NickolasTL, McMahonDJ, ShaneE: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol17: 3223–3232, 2006PubMed
NickolasTL, McMahonDJ, ShaneE: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17: 3223–3232, 2006PubMed)| false
NaylorKL, McArthurE, LeslieWD, FraserL-A, JamalSA, CadaretteSM, et al.: The three-year incidence of fracture in chronic kidney disease. Kidney Int86: 810–818, 2014PubMed
NaylorKL, McArthurE, LeslieWD, FraserL-A, JamalSA, CadaretteSM, et al.: The three-year incidence of fracture in chronic kidney disease. Kidney Int 86: 810–818, 2014PubMed)| false
CocoM, RushH: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis36: 1115–1121, 2000PubMed
CocoM, RushH: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115–1121, 2000PubMed)| false
IsakovaT, CravenTE, SciallaJJ, NickolasTL, SchnallA, BarzilayJ, et al.; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone78: 23–27, 2015PubMed
IsakovaT, CravenTE, SciallaJJ, NickolasTL, SchnallA, BarzilayJ, et al.; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone 78: 23–27, 2015PubMed)| false
ArnesonTJ, LiS, LiuJ, KilpatrickRD, NewsomeBB, St PeterWL: Trends in hip fracture rates in US hemodialysis patients, 1993-2010. Am J Kidney Dis62: 747–754, 2013PubMed
ArnesonTJ, LiS, LiuJ, KilpatrickRD, NewsomeBB, St PeterWL: Trends in hip fracture rates in US hemodialysis patients, 1993-2010. Am J Kidney Dis 62: 747–754, 2013PubMed)| false
NairSS, MitaniAA, GoldsteinBA, ChertowGM, LowenbergDW, WinkelmayerWC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol8: 1336–1342, 2013PubMed
NairSS, MitaniAA, GoldsteinBA, ChertowGM, LowenbergDW, WinkelmayerWC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol 8: 1336–1342, 2013PubMed)| false
KimSM, LiuS, LongJ, Montez-RathME, LeonardMB, ChertowGM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003-2011 nationwide inpatient sample. J Bone Miner Res32: 2297–2303, 2017PubMed
KimSM, LiuS, LongJ, Montez-RathME, LeonardMB, ChertowGM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003-2011 nationwide inpatient sample. J Bone Miner Res 32: 2297–2303, 2017PubMed)| false
GotoNA, WeststrateACG, OosterlaanFM, VerhaarMC, WillemsHC, Emmelot-VonkMH, et al.: The association between chronic kidney disease, falls, and fractures: A systematic review and meta-analysis. Osteoporos Int31: 13–29, 2020PubMed
GotoNA, WeststrateACG, OosterlaanFM, VerhaarMC, WillemsHC, Emmelot-VonkMH, et al.: The association between chronic kidney disease, falls, and fractures: A systematic review and meta-analysis. Osteoporos Int 31: 13–29, 2020PubMed)| false
KimSM, LongJ, Montez-RathM, LeonardM, ChertowGM: Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res31: 1803–1809, 2016PubMed
KimSM, LongJ, Montez-RathM, LeonardM, ChertowGM: Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res 31: 1803–1809, 2016PubMed)| false
MallucheHH, MawadHW, Monier-FaugereM-C: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res26: 1368–1376, 2011PubMed
MallucheHH, MawadHW, Monier-FaugereM-C: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26: 1368–1376, 2011PubMed)| false
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, et al.: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis67: 559–566, 2016PubMed
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, et al.: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67: 559–566, 2016PubMed)| false
IimoriS, MoriY, AkitaW, KuyamaT, TakadaS, AsaiT, et al.: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—A single-center cohort study. Nephrol Dial Transplant27: 345–351, 2012PubMed
IimoriS, MoriY, AkitaW, KuyamaT, TakadaS, AsaiT, et al.: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—A single-center cohort study. Nephrol Dial Transplant 27: 345–351, 2012PubMed)| false
YenchekRH, IxJH, ShlipakMG, BauerDC, RianonNJ, KritchevskySB, et al.; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol7: 1130–1136, 2012PubMed
YenchekRH, IxJH, ShlipakMG, BauerDC, RianonNJ, KritchevskySB, et al.; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7: 1130–1136, 2012PubMed)| false
EvenepoelP, CunninghamJ, FerrariS, HaarhausM, JavaidMK, Lafage-ProustM-H, et al.: European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dialysis Transplant Official Publ European Dialysis Transpl Assoc - European Ren Assoc36: 42–59, 2020
EvenepoelP, CunninghamJ, FerrariS, HaarhausM, JavaidMK, Lafage-ProustM-H, et al.: European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dialysis Transplant Official Publ European Dialysis Transpl Assoc - European Ren Assoc 36: 42–59, 2020)| false
EvenepoelP, CunninghamJ, FerrariS, HaarhausM, JavaidMK, Lafage-ProustM-H, et al.; European Renal Osteodystrophy (EUROD) workgroup; an initiative of the CKD-MBD working group of the ERA-EDTA; and the committee of Scientific Advisors and National Societies of the IOF: Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int32: 2397–2405, 2021PubMed
EvenepoelP, CunninghamJ, FerrariS, HaarhausM, JavaidMK, Lafage-ProustM-H, et al.; European Renal Osteodystrophy (EUROD) workgroup; an initiative of the CKD-MBD working group of the ERA-EDTA; and the committee of Scientific Advisors and National Societies of the IOF: Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 32: 2397–2405, 2021PubMed)| false
Hughes-AustinJM, KatzR, SembaRD, KritchevskySB, BauerDC, SarnakMJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab105: e2903–e2911, 2020PubMed
Hughes-AustinJM, KatzR, SembaRD, KritchevskySB, BauerDC, SarnakMJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab 105: e2903–e2911, 2020PubMed)| false
JaquesDA, HendersonS, DavenportA: Association between bone mineral density at different anatomical sites and both mortality and fracture risk in patients receiving renal replacement therapy: A longitudinal study. Clin Kidney J15: 1188–1195, 2022PubMed
JaquesDA, HendersonS, DavenportA: Association between bone mineral density at different anatomical sites and both mortality and fracture risk in patients receiving renal replacement therapy: A longitudinal study. Clin Kidney J 15: 1188–1195, 2022PubMed)| false
NaylorKL, GargAX, ZouG, LangsetmoL, LeslieWD, FraserL-A, et al.: Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol10: 646–653, 2015PubMed
NaylorKL, GargAX, ZouG, LangsetmoL, LeslieWD, FraserL-A, et al.: Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10: 646–653, 2015PubMed)| false
JamalSA, WestSL, NickolasTL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int25: 71–76, 2014PubMed
JamalSA, WestSL, NickolasTL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25: 71–76, 2014PubMed)| false
PrzedlackiJ, Buczyńska-ChylJ, KoźmińskiP, NiemczykE, WojtaszekE, GieglisE, et al.; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int29: 1105–1115, 2018PubMed
PrzedlackiJ, Buczyńska-ChylJ, KoźmińskiP, NiemczykE, WojtaszekE, GieglisE, et al.; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int 29: 1105–1115, 2018PubMed)| false
NickolasTL, SteinE, CohenA, ThomasV, StaronRB, McMahonDJ, et al.: Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol21: 1371–1380, 2010PubMed
NickolasTL, SteinE, CohenA, ThomasV, StaronRB, McMahonDJ, et al.: Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21: 1371–1380, 2010PubMed)| false
TrombettiA, StoermannC, ChevalleyT, Van RietbergenB, HerrmannFR, MartinP-Y, et al.: Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int24: 1721–1732, 2013PubMed
TrombettiA, StoermannC, ChevalleyT, Van RietbergenB, HerrmannFR, MartinP-Y, et al.: Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int 24: 1721–1732, 2013PubMed)| false
CejkaD, PatschJM, WeberM, DiarraD, RiegerspergerM, KikicZ, et al.: Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol6: 2264–2271, 2011PubMed
CejkaD, PatschJM, WeberM, DiarraD, RiegerspergerM, KikicZ, et al.: Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol 6: 2264–2271, 2011PubMed)| false
NickolasTL, SteinEM, DworakowskiE, NishiyamaKK, Komandah-KossehM, ZhangCA, et al.: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res28: 1811–1820, 2013PubMed
NickolasTL, SteinEM, DworakowskiE, NishiyamaKK, Komandah-KossehM, ZhangCA, et al.: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 1811–1820, 2013PubMed)| false
JamalS, CheungAM, WestS, LokC: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int23: 2805–2813, 2012PubMed
JamalS, CheungAM, WestS, LokC: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 23: 2805–2813, 2012PubMed)| false
SalamS, GallagherO, GossielF, PaggiosiM, KhwajaA, EastellR: Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol29: 1557–1565, 2018PubMed
SalamS, GallagherO, GossielF, PaggiosiM, KhwajaA, EastellR: Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29: 1557–1565, 2018PubMed)| false
PothuaudL, CarcellerP, HansD: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone42: 775–787, 2008PubMed
PothuaudL, CarcellerP, HansD: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone 42: 775–787, 2008PubMed)| false
McCloskeyEV, OdénA, HarveyNC, LeslieWD, HansD, JohanssonH, et al.: A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res31: 940–948, 2016PubMed
McCloskeyEV, OdénA, HarveyNC, LeslieWD, HansD, JohanssonH, et al.: A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31: 940–948, 2016PubMed)| false
IkiM, TamakiJ, KadowakiE, SatoY, DongmeiN, WinzenriethR, et al.: Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res29: 399–407, 2014PubMed
IkiM, TamakiJ, KadowakiE, SatoY, DongmeiN, WinzenriethR, et al.: Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 29: 399–407, 2014PubMed)| false
MuschitzC, KocijanR, HaschkaJ, PahrD, KaiderA, PietschmannP, et al.: TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone79: 259–266, 2015PubMed
MuschitzC, KocijanR, HaschkaJ, PahrD, KaiderA, PietschmannP, et al.: TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79: 259–266, 2015PubMed)| false
LuckmanM, HansD, CortezN, NishiyamaKK, AgarawalS, ZhangC, et al.: Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol12: 644–652, 2017PubMed
LuckmanM, HansD, CortezN, NishiyamaKK, AgarawalS, ZhangC, et al.: Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol 12: 644–652, 2017PubMed)| false
NaylorKL, PriorJ, GargAX, BergerC, LangsetmoL, AdachiJD, et al.: Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol11: 2032–2040, 2016PubMed
NaylorKL, PriorJ, GargAX, BergerC, LangsetmoL, AdachiJD, et al.: Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol 11: 2032–2040, 2016PubMed)| false
MallucheHH, Monier-FaugereMC, BlomquistG, DavenportDL: Two-year cortical and trabecular bone loss in CKD-5D: Biochemical and clinical predictors. Osteoporos Int29: 125–134, 2018PubMed
MallucheHH, Monier-FaugereMC, BlomquistG, DavenportDL: Two-year cortical and trabecular bone loss in CKD-5D: Biochemical and clinical predictors. Osteoporos Int 29: 125–134, 2018PubMed)| false
CoenG, MantellaD, ManniM, BalducciA, NofroniI, SardellaD, et al.: 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int68: 1840–1848, 2005PubMed
CoenG, MantellaD, ManniM, BalducciA, NofroniI, SardellaD, et al.: 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68: 1840–1848, 2005PubMed)| false
TengM, WolfM, OfsthunMN, LazarusJM, HernánMA, CamargoCAJr, et al.: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol16: 1115–1125, 2005PubMed
TengM, WolfM, OfsthunMN, LazarusJM, HernánMA, CamargoCAJr, et al.: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115–1125, 2005PubMed)| false
TengM, WolfM, LowrieE, OfsthunN, LazarusJM, ThadhaniR: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med349: 446–456, 2003PubMed
TengM, WolfM, LowrieE, OfsthunN, LazarusJM, ThadhaniR: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446–456, 2003PubMed)| false
ThadhaniR, AppelbaumE, PritchettY, ChangY, WengerJ, TamezH, et al.: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA307: 674–684, 2012PubMed
ThadhaniR, AppelbaumE, PritchettY, ChangY, WengerJ, TamezH, et al.: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307: 674–684, 2012PubMed)| false
WangAY-M, FangF, ChanJ, WenY-Y, QingS, ChanIH-S, et al.: Effect of paricalcitol on left ventricular mass and function in CKD--The OPERA trial. J Am Soc Nephrol25: 175–186, 2014PubMed
WangAY-M, FangF, ChanJ, WenY-Y, QingS, ChanIH-S, et al.: Effect of paricalcitol on left ventricular mass and function in CKD--The OPERA trial. J Am Soc Nephrol 25: 175–186, 2014PubMed)| false
KhelifiN, DesbiensLC, SidibéA, Mac-WayF: Vitamin D analogues and fracture risk in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. JBMR Plus6: e10611, 2022PubMed
KhelifiN, DesbiensLC, SidibéA, Mac-WayF: Vitamin D analogues and fracture risk in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. JBMR Plus 6: e10611, 2022PubMed)| false
JamalSA, VandermeerB, RaggiP, MendelssohnDC, ChatterleyT, DorganM, et al.: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis. Lancet382: 1268–1277, 2013PubMed
JamalSA, VandermeerB, RaggiP, MendelssohnDC, ChatterleyT, DorganM, et al.: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis. Lancet 382: 1268–1277, 2013PubMed)| false
PatelL, BernardLM, ElderGJ: Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol11: 232–244, 2016PubMed
PatelL, BernardLM, ElderGJ: Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 11: 232–244, 2016PubMed)| false
ChertowGM, BlockGA, Correa-RotterR, DrüekeTB, FloegeJ, GoodmanWG, et al.; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med367: 2482–2494, 2012PubMed
ChertowGM, BlockGA, Correa-RotterR, DrüekeTB, FloegeJ, GoodmanWG, et al.; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482–2494, 2012PubMed)| false
MoeSM, AbdallaS, ChertowGM, ParfreyPS, BlockGA, Correa-RotterR, et al.; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial. J Am Soc Nephrol26: 1466–1475, 2015PubMed
MoeSM, AbdallaS, ChertowGM, ParfreyPS, BlockGA, Correa-RotterR, et al.; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial. J Am Soc Nephrol 26: 1466–1475, 2015PubMed)| false
TsurutaY, OkanoK, KikuchiK, TsurutaY, AkibaT, NittaK: Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol17: 120–126, 2013PubMed
TsurutaY, OkanoK, KikuchiK, TsurutaY, AkibaT, NittaK: Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17: 120–126, 2013PubMed)| false
WetmoreJB, GurevichK, SpragueS, Da RozaG, BuerkertJ, ReinerM, et al.: A randomized trial of cinacalcet versus vitamin d analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol10: 1031–1040, 2015PubMed
WetmoreJB, GurevichK, SpragueS, Da RozaG, BuerkertJ, ReinerM, et al.: A randomized trial of cinacalcet versus vitamin d analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10: 1031–1040, 2015PubMed)| false
BehetsGJ, SpasovskiG, SterlingLR, GoodmanWG, SpiegelDM, De BroeME, et al.: Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int87: 846–856, 2015PubMed
BehetsGJ, SpasovskiG, SterlingLR, GoodmanWG, SpiegelDM, De BroeME, et al.: Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87: 846–856, 2015PubMed)| false
BlockGA, BushinskyDA, ChengS, CunninghamJ, DehmelB, DruekeTB, et al.: Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA317: 156–164, 2017PubMed
BlockGA, BushinskyDA, ChengS, CunninghamJ, DehmelB, DruekeTB, et al.: Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA 317: 156–164, 2017PubMed)| false
PiresGO, VieiraIO, HernandesFR, TeixeiraAL, OliveiraIB, DominguezWV, et al.: Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. Bone121: 277–283, 2019PubMed
PiresGO, VieiraIO, HernandesFR, TeixeiraAL, OliveiraIB, DominguezWV, et al.: Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. Bone 121: 277–283, 2019PubMed)| false
RudserKD, de BoerIH, DooleyA, YoungB, KestenbaumB: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol18: 2401–2407, 2007PubMed
RudserKD, de BoerIH, DooleyA, YoungB, KestenbaumB: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18: 2401–2407, 2007PubMed)| false
TitanSM, LaureatiP, SangY, ChangAR, EvansM, TrevisanM, et al.: Bisphosphonate utilization across the spectrum of eGFR. Arch Osteoporos15: 69, 2020PubMed
TitanSM, LaureatiP, SangY, ChangAR, EvansM, TrevisanM, et al.: Bisphosphonate utilization across the spectrum of eGFR. Arch Osteoporos 15: 69, 2020PubMed)| false
MillerPD, RouxC, BoonenS, BartonIP, DunlapLE, BurgioDE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res20: 2105–2115, 2005PubMed
MillerPD, RouxC, BoonenS, BartonIP, DunlapLE, BurgioDE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105–2115, 2005PubMed)| false
JamalSA, BauerDC, EnsrudKE, CauleyJA, HochbergM, IshaniA, et al.: Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res22: 503–508, 2007PubMed
JamalSA, BauerDC, EnsrudKE, CauleyJA, HochbergM, IshaniA, et al.: Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 22: 503–508, 2007PubMed)| false
ShigematsuT, MuraokaR, SugimotoT, NishizawaY: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol18: 66, 2017PubMed
ShigematsuT, MuraokaR, SugimotoT, NishizawaY: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol 18: 66, 2017PubMed)| false
SugimotoT, InoueD, MaeharaM, OikawaI, ShigematsuT, NishizawaY: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab37: 730–740, 2019PubMed
SugimotoT, InoueD, MaeharaM, OikawaI, ShigematsuT, NishizawaY: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab 37: 730–740, 2019PubMed)| false
BergnerR, HenrichD, HoffmannM, Schmidt-GaykH, LenzT, UpperkampM: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol21: 510–516, 2008PubMed
BergnerR, HenrichD, HoffmannM, Schmidt-GaykH, LenzT, UpperkampM: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 21: 510–516, 2008PubMed)| false
AliMS, ErnstM, RobinsonDE, CaskeyF, ArdenNK, Ben-ShlomoY, et al.: Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos15: 81, 2020PubMed
AliMS, ErnstM, RobinsonDE, CaskeyF, ArdenNK, Ben-ShlomoY, et al.: Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos 15: 81, 2020PubMed)| false
FujitaR, OtaM, SatoD, NakazawaD, Kimura-SudaH, NakamuraF, et al.: Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tissue Int107: 389–402, 2020PubMed
FujitaR, OtaM, SatoD, NakazawaD, Kimura-SudaH, NakamuraF, et al.: Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tissue Int 107: 389–402, 2020PubMed)| false
SwallowEA, ArefMW, MetzgerCE, SacksS, LehmkuhlerDR, ChenN, et al.: Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone127: 419–426, 2019PubMed
SwallowEA, ArefMW, MetzgerCE, SacksS, LehmkuhlerDR, ChenN, et al.: Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone 127: 419–426, 2019PubMed)| false
SchiniM, PeelN, Toronjo-UrquizaL, ThomasE, SalamS, KhwajaA, et al.: Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int33: 737–744, 2022PubMed
SchiniM, PeelN, Toronjo-UrquizaL, ThomasE, SalamS, KhwajaA, et al.: Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int 33: 737–744, 2022PubMed)| false
AlarkawiD, AliMS, BliucD, PallaresN, TebeC, ElhusseinL, et al.: Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: A population-based cohort study. J Bone Miner Res35: 894–900, 2020PubMed
AlarkawiD, AliMS, BliucD, PallaresN, TebeC, ElhusseinL, et al.: Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: A population-based cohort study. J Bone Miner Res 35: 894–900, 2020PubMed)| false
RobinsonDE, AliMS, PallaresN, TebéC, ElhusseinL, AbrahamsenB, et al.: Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: A bi-national cohort analysis. J Bone Miner Res36: 820–832, 2021
RobinsonDE, AliMS, PallaresN, TebéC, ElhusseinL, AbrahamsenB, et al.: Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: A bi-national cohort analysis. J Bone Miner Res 36: 820–832, 2021)| false
RobinsonDE, AliMS, StraussVY, ElhusseinL, AbrahamsenB, ArdenNK, et al.: Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: A propensity score-matched cohort study. Health Technol Assess25: 1–106, 2021PubMed
RobinsonDE, AliMS, StraussVY, ElhusseinL, AbrahamsenB, ArdenNK, et al.: Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: A propensity score-matched cohort study. Health Technol Assess 25: 1–106, 2021PubMed)| false
CummingsSR, San MartinJ, McClungMR, SirisES, EastellR, ReidIR, et al.; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med361: 756–765, 2009PubMed
CummingsSR, San MartinJ, McClungMR, SirisES, EastellR, ReidIR, et al.; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765, 2009PubMed)| false
JamalSA, LjunggrenO, Stehman-BreenC, CummingsSR, McClungMR, GoemaereS, et al.: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res26: 1829–1835, 2011PubMed
JamalSA, LjunggrenO, Stehman-BreenC, CummingsSR, McClungMR, GoemaereS, et al.: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 1829–1835, 2011PubMed)| false
BroadwellA, ChinesA, EbelingPR, FranekE, HuangS, SmithS, et al.: Denosumab safety and efficacy among participants in the FREEDOM Extension Study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab106: 397–409, 2021PubMed
BroadwellA, ChinesA, EbelingPR, FranekE, HuangS, SmithS, et al.: Denosumab safety and efficacy among participants in the FREEDOM Extension Study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106: 397–409, 2021PubMed)| false
HiramatsuR, UbaraY, SawaN, SakaiA: Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant36: 1900–1907, 2021PubMed
HiramatsuR, UbaraY, SawaN, SakaiA: Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant 36: 1900–1907, 2021PubMed)| false
BlockGA, BoneHG, FangL, LeeE, PadhiD: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res27: 1471–1479, 2012PubMed
BlockGA, BoneHG, FangL, LeeE, PadhiD: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27: 1471–1479, 2012PubMed)| false
ChenC-L, ChenN-C, HsuC-Y, ChouK-J, LeeP-T, FangH-C, et al.: An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab99: 2426–2432, 2014PubMed
ChenC-L, ChenN-C, HsuC-Y, ChouK-J, LeeP-T, FangH-C, et al.: An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99: 2426–2432, 2014PubMed)| false
BonaniM, FreyD, BrockmannJ, FehrT, MuellerTF, SalehL, et al.: Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: A randomized controlled trial. Am J Transplant16: 1882–1891, 2016PubMed
BonaniM, FreyD, BrockmannJ, FehrT, MuellerTF, SalehL, et al.: Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: A randomized controlled trial. Am J Transplant 16: 1882–1891, 2016PubMed)| false
KobelC, FreyD, GrafN, WüthrichRP, BonaniM: Follow-up of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the receptor activator of nuclear factor κB ligand inhibitor denosumab. Kidney Blood Press Res44: 1285–1293, 2019PubMed
KobelC, FreyD, GrafN, WüthrichRP, BonaniM: Follow-up of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the receptor activator of nuclear factor κB ligand inhibitor denosumab. Kidney Blood Press Res 44: 1285–1293, 2019PubMed)| false
NeerRM, ArnaudCD, ZanchettaJR, PrinceR, GaichGA, ReginsterJY, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med344: 1434–1441, 2001PubMed
NeerRM, ArnaudCD, ZanchettaJR, PrinceR, GaichGA, ReginsterJY, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441, 2001PubMed)| false
SaagKG, ShaneE, BoonenS, MarínF, DonleyDW, TaylorKA, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med357: 2028–2039, 2007PubMed
SaagKG, ShaneE, BoonenS, MarínF, DonleyDW, TaylorKA, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028–2039, 2007PubMed)| false
MillerPD, SchwartzEN, ChenP, MisurskiDA, KregeJH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int18: 59–68, 2007PubMed
MillerPD, SchwartzEN, ChenP, MisurskiDA, KregeJH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18: 59–68, 2007PubMed)| false
ImaiH, WatanabeM, FujitaT, WatanabeH, HaradaK, MoritoyoT; ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther52: 166–174, 2014PubMed
ImaiH, WatanabeM, FujitaT, WatanabeH, HaradaK, MoritoyoT; ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther 52: 166–174, 2014PubMed)| false
CejkaD, KodrasK, BaderT, HaasM: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res33: 221–226, 2010PubMed
CejkaD, KodrasK, BaderT, HaasM: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res 33: 221–226, 2010PubMed)| false
SumidaK, UbaraY, HoshinoJ, MiseK, HayamiN, SuwabeT, et al.: Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study. Osteoporos Int27: 1441–1450, 2016PubMed
SumidaK, UbaraY, HoshinoJ, MiseK, HayamiN, SuwabeT, et al.: Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study. Osteoporos Int 27: 1441–1450, 2016PubMed)| false
BaharH, GallacherK, DownallJ, NelsonCA, ShomaliM, HattersleyG: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int99: 489–499, 2016PubMed
BaharH, GallacherK, DownallJ, NelsonCA, ShomaliM, HattersleyG: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99: 489–499, 2016PubMed)| false
LederBZ, O’DeaLSL, ZanchettaJR, KumarP, BanksK, McKayK, et al.: Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab100: 697–706, 2015PubMed
LederBZ, O’DeaLSL, ZanchettaJR, KumarP, BanksK, McKayK, et al.: Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100: 697–706, 2015PubMed)| false
MillerPD, HattersleyG, RiisBJ, WilliamsGC, LauE, RussoLA, et al.; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA316: 722–733, 2016PubMed
MillerPD, HattersleyG, RiisBJ, WilliamsGC, LauE, RussoLA, et al.; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 316: 722–733, 2016PubMed)| false
MoreiraCA, FitzpatrickLA, WangY, ReckerRR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone97: 314–319, 2017PubMed
MoreiraCA, FitzpatrickLA, WangY, ReckerRR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone 97: 314–319, 2017PubMed)| false
BilezikianJP, HattersleyG, MitlakBH, HuM-Y, FitzpatrickLA, DabrowskiC, et al.: Abaloparatide in patients with mild or moderate renal impairment: Results from the ACTIVE phase 3 trial. Curr Med Res Opin35: 2097–2102, 2019PubMed
BilezikianJP, HattersleyG, MitlakBH, HuM-Y, FitzpatrickLA, DabrowskiC, et al.: Abaloparatide in patients with mild or moderate renal impairment: Results from the ACTIVE phase 3 trial. Curr Med Res Opin 35: 2097–2102, 2019PubMed)| false
CosmanF, CrittendenDB, AdachiJD, BinkleyN, CzerwinskiE, FerrariS, et al.: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med375: 1532–1543, 2016PubMed
CosmanF, CrittendenDB, AdachiJD, BinkleyN, CzerwinskiE, FerrariS, et al.: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375: 1532–1543, 2016PubMed)| false
McClungMR, GrauerA, BoonenS, BologneseMA, BrownJP, Diez-PerezA, et al.: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med370: 412–420, 2014PubMed
McClungMR, GrauerA, BoonenS, BologneseMA, BrownJP, Diez-PerezA, et al.: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412–420, 2014PubMed)| false
SaagKG, PetersenJ, BrandiML, KaraplisAC, LorentzonM, ThomasT, et al.: Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med377: 1417–1427, 2017PubMed
SaagKG, PetersenJ, BrandiML, KaraplisAC, LorentzonM, ThomasT, et al.: Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377: 1417–1427, 2017PubMed)| false
LangdahlBL, LibanatiC, CrittendenDB, BologneseMA, BrownJP, DaizadehNS, et al.: Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet390: 1585–1594, 2017PubMed
LangdahlBL, LibanatiC, CrittendenDB, BologneseMA, BrownJP, DaizadehNS, et al.: Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet 390: 1585–1594, 2017PubMed)| false
MillerPD, AdachiJD, AlbergariaBH, CheungAM, ChinesAA, GielenE, et al.: Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res37: 1437–1445, 2022PubMed
MillerPD, AdachiJD, AlbergariaBH, CheungAM, ChinesAA, GielenE, et al.: Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37: 1437–1445, 2022PubMed)| false
SatoM, InabaM, YamadaS, EmotoM, OhnoY, TsujimotoY: Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab39: 1082–1090, 2021PubMed
SatoM, InabaM, YamadaS, EmotoM, OhnoY, TsujimotoY: Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39: 1082–1090, 2021PubMed)| false
HaraT, HijikataY, MatsubaraY, WatanabeN: Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database Syst Rev7: CD013424, 2021PubMed
HaraT, HijikataY, MatsubaraY, WatanabeN: Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database Syst Rev 7: CD013424, 2021PubMed)| false
